MICHAEL KRANDA

Corporate Board Profile

Tech Score: 0/100

PTC THERAPEUTICS, INC.

Filing Date	Source Excerpt
2014-04-28	Michael Kranda Audit Committee Age 59 Mr. Kranda has served as a member of our Board since December 2003. Since September 2006, Mr. Kranda has served as a consultant to Vulcan Capital, the private investment group of Vulcan Inc., and Mr. Kranda served as Managing Director of biotechnology venture investments at Vulcan Capital from September 2003 to September 2006. From July 1996 to July 2002, Mr. Kranda served as Chief Executive Officer at Oxford GlycoSciences, a biotechnology company. Prior to joining Oxford GlycoSciences, Mr. Kranda was President and Chief Operating Officer at Immunex Corporation (now Amgen), a biopharmaceutical company. Mr. Kranda currently serves as Chief Executive Officer and a director of BEAT BioTherapeutics Corporation, a gene therapy company. Mr. Kranda received a B.A. and an M.B.A from the University of Washington School of Business. We believe that Mr. Kranda is qualified to serve on our Board because of his many years of service as one of our directors, his extensive experience in the life sciences industry and his service on the boards of directors of other life sciences companies.
2016-04-28	Michael Kranda() 2015 Director Compensation Table: Michael Kranda Fees earned or paid in cash $29,000 Option awards $948,560 All other compensation $29,000 Total $1,006,560 () Messrs. Aldrich and Kranda ceased their service on the Board of Directors on June 10, 2015.

Filing Date

Source Excerpt

2014-04-28

Michael Kranda Audit Committee Age 59 Mr. Kranda has served as a member of our Board since December 2003. Since September 2006, Mr. Kranda has served as a consultant to Vulcan Capital, the private investment group of Vulcan Inc., and Mr. Kranda served as Managing Director of biotechnology venture investments at Vulcan Capital from September 2003 to September 2006. From July 1996 to July 2002, Mr. Kranda served as Chief Executive Officer at Oxford GlycoSciences, a biotechnology company. Prior to joining Oxford GlycoSciences, Mr. Kranda was President and Chief Operating Officer at Immunex Corporation (now Amgen), a biopharmaceutical company. Mr. Kranda currently serves as Chief Executive Officer and a director of BEAT BioTherapeutics Corporation, a gene therapy company. Mr. Kranda received a B.A. and an M.B.A from the University of Washington School of Business. We believe that Mr. Kranda is qualified to serve on our Board because of his many years of service as one of our directors, his extensive experience in the life sciences industry and his service on the boards of directors of other life sciences companies.

2016-04-28

Michael Kranda(*) 2015 Director Compensation Table: Michael Kranda Fees earned or paid in cash $29,000 Option awards $948,560 All other compensation $29,000 Total $1,006,560 (*) Messrs. Aldrich and Kranda ceased their service on the Board of Directors on June 10, 2015.

Data sourced from SEC filings. Last updated: 2026-03-14